Literature DB >> 19373196

Chlamydia screening among sexually active young female enrollees of health plans--United States, 2000-2007.

.   

Abstract

Chlamydia trachomatis infection is the most common bacterial sexually transmitted disease (STD) in the United States, with more than 2.8 million new cases estimated to occur each year. During 2007, approximately 1.1 million cases of chlamydia were reported to CDC; more than half of these were in females aged 15-25 years. Untreated chlamydia can progress to pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and chronic pelvic pain. In 1989, the U.S. Preventive Services Task Force (USPSTF) recommended routine chlamydia screening of sexually active young women. To evaluate the rates of chlamydia screening among sexually active young females, CDC analyzed data reported by commercial and Medicaid health plans to the Healthcare Effectiveness Data and Information Set (HEDIS) during 2000-2007. The percentage of enrolled sexually active females who were screened for chlamydia was estimated for each of 41 states that had at least five health plans reporting HEDIS chlamydia screening data and for four U.S. geographic regions. Nationally, the annual screening rate increased from 25.3% in 2000 to 43.6% in 2006, and then decreased slightly to 41.6% in 2007. The regional rate of chlamydia screening in 2007 was highest in the Northeast (45.5%) and lowest in the South (37.3%). Increased screening by health-care providers is necessary to reduce the burden of chlamydial infection in the United States.

Entities:  

Mesh:

Year:  2009        PMID: 19373196

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  67 in total

Review 1.  Sexually transmitted disease (STD) update: a review of the CDC 2010 STD treatment guidelines and epidemiologic trends of common STDs in Hawai'i.

Authors:  Alan R Katz; Maria Veneranda C Lee; Glenn M Wasserman
Journal:  Hawaii J Med Public Health       Date:  2012-03

2.  Comparison of adherence to chlamydia screening guidelines among Title X providers and non-Title X providers in the California Family Planning, Access, Care, and Treatment Program.

Authors:  Joan M Chow; Heike Thiel de Bocanegra; Denis Hulett; Hye-Youn Park; Philip Darney
Journal:  J Womens Health (Larchmt)       Date:  2012-06-13       Impact factor: 2.681

3.  Chlamydia screening of adolescent females: a survey of providers in Hawaii.

Authors:  Chika Muto McGrath; Alan R Katz; Maria Veneranda C Lee; Roger W Rochat
Journal:  J Community Health       Date:  2011-04

4.  Bridging the gap: using school-based health services to improve chlamydia screening among young women.

Authors:  Rebecca A Braun; Jackie M Provost
Journal:  Am J Public Health       Date:  2010-07-15       Impact factor: 9.308

5.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

Review 6.  Toll-like receptors in pregnancy disorders and placental dysfunction.

Authors:  Joan K Riley; D Michael Nelson
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

7.  Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate model.

Authors:  Chunmei Cheng; Sukumar Pal; Ilham Bettahi; Kristie L Oxford; Peter A Barry; Luis M de la Maza
Journal:  Vaccine       Date:  2011-03-04       Impact factor: 3.641

8.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

9.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

10.  Cost-Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S.

Authors:  Kwame Owusu-Edusei; Karen W Hoover; Thomas L Gift
Journal:  Am J Prev Med       Date:  2016-03-04       Impact factor: 5.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.